Randomized controlled trial of abituzumab in systemic sclerosis-associated interstitial lung disease

D. Khanna (Ann Arbor, United States of America)

Source: International Congress 2017 – New ideas for the management of chronic lung diseases
Session: New ideas for the management of chronic lung diseases
Session type: Oral Presentation
Number: 2930
Disease area: Interstitial lung diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Khanna (Ann Arbor, United States of America). Randomized controlled trial of abituzumab in systemic sclerosis-associated interstitial lung disease. 2930

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Clinical trials in interstitial lung disease
Source: Eur Respir Mon; 2009: 46: 67–84
Year: 2009

Bosentan does not improve outcome in patients with steroid-resistant pulmonary sarcoidosis – Results from a double-blind placebo-controlled phase 2 trial
Source: International Congress 2014 – Sarcoidosis
Year: 2014

Randomised controlled, crossover trial to evaluate the effects of ambulatory oxygen on health status in patients with fibrotic lung disease
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016


Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Source: Eur Respir J 2013; 42: 1622-1632
Year: 2013



Preliminary results of pulmonary rehabilitation in interstitial lung diseases: A randomised controlled trial B32220095560
Source: Annual Congress 2011 - Exercise training: new populations, new techniques
Year: 2011


A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 6
Year: 2014


The effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis- A randomised controlled trial
Source: International Congress 2017 – Best abstracts in pulmonary rehabilitation and chronic care
Year: 2017




Heliox and alveolar oxygenation in patients with chronic obstructive pulmonary disease: a multicentre, randomised, crossover study
Source: Eur Respir J 2004; 24: Suppl. 48, 243s
Year: 2004

External validity of randomised controlled trials in idiopathic pulmonary fibrosis
Source: Eur Respir J 2006; 27: 1072
Year: 2006


Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune alveolar proteinosis (aPAP)
Source: International Congress 2016 – Orphan diseases I
Year: 2016

Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial.
Source: Virtual Congress 2020 – Chronic cough: only symptom or disease?
Year: 2020




Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial
Source: ERJ Open Res, 5 (3) 00110-2019; 10.1183/23120541.00110-2019
Year: 2019



Non-invasive positive pressure ventilation (NIPPV)for acute exacerbations of chronic obstructive pulmonary disease: a multicentre randomized controlled trial
Source: Eur Respir J 2003; 22: Suppl. 45, 403s
Year: 2003

Concomitant corticosteroid with anti-fibrotic therapy for idiopathic pulmonary fibrosis: a prospective multicenter study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021


RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial
Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs
Year: 2021



Early treatment of borderline pulmonary arterial hypertension associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group, proof-of-concept study
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Year: 2018


Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial
Source: Eur Respir J 2007; 30: Suppl. 51, 525s
Year: 2007

Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018

Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019


A multicentre randomised controlled trial of inspiratory muscle training for patients with chronic obstructive pulmonary disease (IMTCO study)
Source: International Congress 2017 – Exercise training and breathing exercises in chronic respiratory disease
Year: 2017